Read full article
Платон Щукин (Редактор отдела «Экономика»)
。旺商聊官方下载对此有专业解读
Copyright © 1997-2026 by www.people.com.cn all rights reserved
Infigratinib靶向的FGFR3（成纤维细胞生长因子受体3）正是驱动ACH疾病发生的关键靶点，2月12日，BridgeBio公布Infigratinib在ACH中取得的首个具有统计学显著改善意义的3期顶线结果，公司计划下半年向FDA提交新药申请。
�o�T�FMicrosoft, Google rule AI vendor market for enterprises�iCIO Dive�j��1�FGartner Identifies the Companies to Beat in the AI Vendor Race�iGarther�j��2�FPalo Alto Networks shares surge after company releases strong annual forecast�iCybersecurity Dive�j��3�FCIOs name AI adoption as top imperative: survey�iCIO Dive�j��4�FStuck in the pilot phase: Enterprises grapple with generative AI ROI�iCIO Dive�j��5�FGlobal Data Leaders Seek to Harness the Power of GenAI for AI-Driven Success�iCIO Dive�j��6�FMicrosoft 365 to include more AI tools - at a higher price�iCIO Dive�j��7�F5 CIO predictions for AI in 2026�iCIO Dive�j